Nisa Investment Advisors LLC Buys 16,947 Shares of Gilead Sciences, Inc. $GILD

Nisa Investment Advisors LLC grew its position in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 4.9% in the 2nd quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 362,516 shares of the biopharmaceutical company’s stock after purchasing an additional 16,947 shares during the quarter. Nisa Investment Advisors LLC’s holdings in Gilead Sciences were worth $40,192,000 as of its most recent SEC filing.

A number of other institutional investors also recently modified their holdings of the stock. Smallwood Wealth Investment Management LLC bought a new position in shares of Gilead Sciences during the 1st quarter worth about $25,000. Activest Wealth Management grew its stake in shares of Gilead Sciences by 2,837.5% in the 1st quarter. Activest Wealth Management now owns 235 shares of the biopharmaceutical company’s stock worth $26,000 after acquiring an additional 227 shares in the last quarter. Harbor Asset Planning Inc. bought a new position in shares of Gilead Sciences during the second quarter valued at about $27,000. Goodman Advisory Group LLC purchased a new position in Gilead Sciences during the first quarter worth about $29,000. Finally, Colonial Trust Advisors grew its position in Gilead Sciences by 304.3% in the 1st quarter. Colonial Trust Advisors now owns 283 shares of the biopharmaceutical company’s stock worth $32,000 after purchasing an additional 213 shares in the last quarter. Institutional investors and hedge funds own 83.67% of the company’s stock.

Insider Activity

In related news, insider Johanna Mercier sold 3,000 shares of the firm’s stock in a transaction on Wednesday, October 15th. The shares were sold at an average price of $118.08, for a total transaction of $354,240.00. Following the completion of the transaction, the insider owned 110,193 shares of the company’s stock, valued at $13,011,589.44. This trade represents a 2.65% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CFO Andrew D. Dickinson sold 2,500 shares of Gilead Sciences stock in a transaction dated Wednesday, October 15th. The shares were sold at an average price of $118.08, for a total transaction of $295,200.00. Following the completion of the sale, the chief financial officer owned 157,055 shares in the company, valued at approximately $18,545,054.40. This trade represents a 1.57% decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 71,500 shares of company stock valued at $8,281,540. 0.27% of the stock is currently owned by company insiders.

Wall Street Analysts Forecast Growth

GILD has been the topic of several research analyst reports. Cantor Fitzgerald upped their price target on shares of Gilead Sciences from $129.00 to $135.00 and gave the stock an “overweight” rating in a report on Thursday, October 9th. TD Cowen upped their price objective on Gilead Sciences from $115.00 to $125.00 and gave the stock a “buy” rating in a report on Thursday. Daiwa America upgraded Gilead Sciences from a “hold” rating to a “strong-buy” rating in a research report on Tuesday, August 19th. Daiwa Capital Markets raised shares of Gilead Sciences from a “neutral” rating to an “outperform” rating and set a $128.00 price target on the stock in a research note on Tuesday, August 19th. Finally, Weiss Ratings reiterated a “buy (b)” rating on shares of Gilead Sciences in a report on Saturday. One equities research analyst has rated the stock with a Strong Buy rating, twenty have issued a Buy rating and six have given a Hold rating to the company. Based on data from MarketBeat.com, Gilead Sciences presently has an average rating of “Moderate Buy” and a consensus target price of $122.61.

Gilead Sciences Stock Up 0.2%

NASDAQ GILD opened at $120.94 on Friday. The company has a current ratio of 1.32, a quick ratio of 1.15 and a debt-to-equity ratio of 1.13. Gilead Sciences, Inc. has a 12 month low of $86.08 and a 12 month high of $124.61. The stock’s 50 day moving average is $115.47 and its 200 day moving average is $111.07. The stock has a market cap of $150.06 billion, a PE ratio of 24.09, a P/E/G ratio of 0.83 and a beta of 0.34.

Gilead Sciences (NASDAQ:GILD) last released its earnings results on Thursday, August 7th. The biopharmaceutical company reported $2.01 EPS for the quarter, topping the consensus estimate of $1.96 by $0.05. Gilead Sciences had a net margin of 21.86% and a return on equity of 50.99%. The firm had revenue of $7.08 billion for the quarter, compared to the consensus estimate of $6.95 billion. During the same quarter in the previous year, the firm earned $2.01 earnings per share. The company’s quarterly revenue was up 1.4% compared to the same quarter last year. Gilead Sciences has set its FY 2025 guidance at 7.950-8.250 EPS. Research analysts predict that Gilead Sciences, Inc. will post 7.95 EPS for the current fiscal year.

Gilead Sciences Announces Dividend

The company also recently announced a quarterly dividend, which was paid on Monday, September 29th. Stockholders of record on Monday, September 15th were issued a $0.79 dividend. This represents a $3.16 annualized dividend and a dividend yield of 2.6%. The ex-dividend date of this dividend was Monday, September 15th. Gilead Sciences’s payout ratio is 62.95%.

Gilead Sciences Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.